Summary of functional assays for phenotypic ERG variants in this study
| Variant . | Phenotypes . | Transactivation . | DNA binding . | Subcellular localization . | FLC myeloid differentiation . | FLC cytokine independence . | Leukemogenesis assay . | ACMG classification . |
|---|---|---|---|---|---|---|---|---|
| WT | NA | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | NA |
| I126T | AML | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| P116R | Cytopenia | ✓✓✓✓ | ✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | VUS |
| R302C | CLL | ✓✓✓✓ | ND | ✓✓✓✓ | ND | ND | ND | VUS |
| K380N | Cytopenia | ✓✓✓✓ | ✓✓✓ | ✓ | ND | ND | ND | P |
| P306L | Lymphedema | ✓✓✓ | ND | ✓✓✓✓ | ND | ND | ND | VUS |
| G394W | AML | ✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| M341V | Cytopenia | ✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| D345N | MDS | ✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✖ | VUS |
| D363A | MDS | ✓✓ | ✖ | ✓✓✓✓ | ND | ND | ND | VUS |
| Y388C | Lymphedema | ✖ | ND | ✓✓✓✓ | ND | ND | ND | LP |
| R370H | Cytopenia | ✖ | ✖ | ✓✓ | ND | ND | ND | P |
| R370P | Cytopenia + MDS | ✖ | ✖ | ✓✓ | ✖ | ✖ | ✖ | P |
| Y373C | Cytopenia + AML | ✖ | ✖ | ✓ | ✖ | ✖ | ✖ | LP |
| Y372∗ | Cytopenia | ✖ | ✖ | ✓ | ✖ | ✖ | ✖ | P |
| E20Vfs∗13 | MDS | ND | ND | ND | ND | ND | ND | VUS |
| V127Efs∗82 | ALL | ND | ND | ND | ND | ND | ND | VUS |
| Variant . | Phenotypes . | Transactivation . | DNA binding . | Subcellular localization . | FLC myeloid differentiation . | FLC cytokine independence . | Leukemogenesis assay . | ACMG classification . |
|---|---|---|---|---|---|---|---|---|
| WT | NA | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | NA |
| I126T | AML | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| P116R | Cytopenia | ✓✓✓✓ | ✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | VUS |
| R302C | CLL | ✓✓✓✓ | ND | ✓✓✓✓ | ND | ND | ND | VUS |
| K380N | Cytopenia | ✓✓✓✓ | ✓✓✓ | ✓ | ND | ND | ND | P |
| P306L | Lymphedema | ✓✓✓ | ND | ✓✓✓✓ | ND | ND | ND | VUS |
| G394W | AML | ✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| M341V | Cytopenia | ✓✓ | ✓✓✓✓ | ✓✓✓✓ | ND | ND | ND | VUS |
| D345N | MDS | ✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✓✓✓✓ | ✖ | VUS |
| D363A | MDS | ✓✓ | ✖ | ✓✓✓✓ | ND | ND | ND | VUS |
| Y388C | Lymphedema | ✖ | ND | ✓✓✓✓ | ND | ND | ND | LP |
| R370H | Cytopenia | ✖ | ✖ | ✓✓ | ND | ND | ND | P |
| R370P | Cytopenia + MDS | ✖ | ✖ | ✓✓ | ✖ | ✖ | ✖ | P |
| Y373C | Cytopenia + AML | ✖ | ✖ | ✓ | ✖ | ✖ | ✖ | LP |
| Y372∗ | Cytopenia | ✖ | ✖ | ✓ | ✖ | ✖ | ✖ | P |
| E20Vfs∗13 | MDS | ND | ND | ND | ND | ND | ND | VUS |
| V127Efs∗82 | ALL | ND | ND | ND | ND | ND | ND | VUS |
ERG variants are ordered in descending order of transactivation ability. Ticks (✓) indicate degree of WT-like activity in transactivation, DNA binding, subcellular localization, FLC myeloid differentiation, FLC cytokine independence, and leukemogenesis assays. ✖ indicates complete LOF in these assays.
CLL, chronic lymphocytic leukemia; LP, likely pathogenic; NA, not applicable; ND, not determined; P, pathogenic.